INTRODUCTION
Primary hypothyroidism is one of the most common endocrine disorders. Replacement therapy with revived interest in the combination of L-T4 and L-T3. A number of published studies furnish evidence of favourable changes in the psychological indicators of the combined therapy L-T4+L-T3 compared to monotherapy with L-T4. 3, 4 Other researchers, however, do not confirm the advantages of the combined therapy compared to monotherapy. [1] [2] [3] [4] [5] [6] [7] [8] [9] The objective of this study was to compare various parameters in patients with hypothyroidism receiving either monotherapy with L-T4 or combination therapy with L-T4 and L-T3.
MATERIALS AND METHODS

Patients
We conducted a randomized controlled study in 36 premenopausal women with untreated overt primary hypothyroidism (reduced T4 concentration accompanied by increased TSH concentration at the time of initial diagnosis). The patients were divided into two groups: patients in Group A (n=20) received L-T4 at the dose of 1.6 µg per kg, while in Group B (n=16) patients received the combination of L-T4+L-T3. In the combination therapy the calculated dose of L-T4 was reduced by 25 µg and replaced by 12.5 µg of L-T3 (Table 1) . We used block randomization (applying a table of random). The treatment period lasted for 6 months. Patients were examined at baseline and at the end of the treatment period. Assessment was carried out after overnight fasting and before taking the thyroid preparation. The clinical characteristics of the patients at baseline are summarized in Table 1 .
Blood samples were obtained to determine serum TSH, free T4, free T3, lipid profile, and osteocalcin. Urine samples were collected to determine urinary deoxypyridinoline and creatinine. 24-hour ECGmonitoring and osteodensitometry were also carried out at baseline and at the end of a 6-month period.
Exclusion criteria were the following: peri-and postmenopause, pregnancy, obesity (BMI >30 kg/ m 2 ), major comorbidity, and use of drugs that affect metabolism or bioavailability of thyroid hormones preparations. The study was approved by the Institutional Ethics Committee and subjects gave informed consent.
Methods
Serum TSH (reference range: 0.4 -4 mU/l), fT4 (reference range: 11.5 -23.2 pmol/l) and fT3 (reference range: 3.2 -7.2 pmol/l) were measured by an immunochemiluminescence method ("Immulite", Diagnostic Products Corporation, Los Angeles, USA). Blood samples were collected in the morning before the thyroid preparation was taken. Osteocalcin (reference range: 3.1 -13.3 ng/ml) and deoxypyridinoline (reference range: 3.0 -7.4 nM/mM creatinine) were measured by an immunochemiluminescence method. Total cholesterol (normal range: 3.1 -5.2 mmol/L), triglycerides (TG) (normal range: 0.5 -2.0 mmol/L), high density lipoprotein cholesterol (HDL) (normal range: 0.9 -1.9 mmol/L), and very low density lipoprotein cholesterol (VLDL) (normal range: 0.2 -1.0 mmol/L) were determined using the commercial set "Vital-Diagnostic" (St. Petersburg, Russia) on an "Eos-bravo" autoanalyzer (Hospitex Diagnostics, Italy). LDL cholesterol was calculated according to the equation: low density lipoproteins cholesterol (LDL) = total cholesterol -HDL -triglycerides/2.2.
24-hour ECG monitoring and analysis was performed using a 2-channels SCHILLER MT-100 ECGdevice and an MT-200 operating system (Schiller AG, Switzerland). Bone mass measurement was conducted at forearm using dual energy X-ray bone densitometer "DTX-200" ("Osteometer").
Symptoms of hypothyroidism were assessed using the 4-point scale, ranging from 0 to 3. In the scale, twelve of the most common symptoms of hypothyroidism were included. At the final visit patients were The baseline lipoprotein profiles in the two groups were comparable. However, the changes in total cholesterol during the study period were different in the two groups (Table 3, Figure 1 ) In the patients of group A, the total cholesterol did not significantly change compared to baseline (Figure 1 ), while in Group B, the level of serum cholesterol decreased significantly and was lower compared to Group A at the end of treatment. Analogous changes were disclosed with regard to LDL cholesterol levels ( Table 3) . No significant difference between monotherapy and combined therapy was observed in TG and HDL levels.
Holter ECG monitoring
Holter ECG monitoring was conducted in each patient at baseline and at the end of the 6 months' treatment. There was no significant difference between monotherapy and combined therapy on the minimum, maximum, and mean heart rate. Also, the mean heart rate analyzed 2 hours after the administration of thyroid hormone preparations did not differ between monotherapy and combined therapy (Table 4 ).
Bone metabolism
There was no significant difference between treatments in serum osteocalcin. Nevertheless, in Group B asked which treatment they preferred.
Statistical analysis
Statistical analysis was performed using the STA- 
RESULTS
Clinical findings
The clinical characteristics of the patients at baseline did not differ in the two groups (Table 1) .
Biochemistry results
At baseline, serum TSH values were above the upper limit of the normal range in all 36 patients and there was no difference between Groups A and B (Table 2) . At six months, no significant difference between treatments was detected with regard to TSH levels.
Lipoprotein profiles
At baseline, total cholesterol was above the upper limit of the normal range (>5.2 mmol/liter) in 23 of 36 patients (66%), while LDL cholesterol was above (Table 5 ). The changes were not significantly different (T= 208.0; p >0.05). The urine deoxypyridinoline in group B significantly increased after combined therapy and was higher than in group A at the end of therapy (p <0.05) (Figure 2) . No significant difference between monotherapy with L-T4 and combined therapy was revealed in densitometry. 
Preference of treatment
At the final visit patients were asked which treatment they preferred. Of 36 study patients, 10 preferred L-T4+L-T3 treatment (27.8%), 8 preferred L-T4 treatment (22.2%), and 18 patients (50%) had no preference.
DISCUSSION
In a previous study 10 we compared the effect of L-T4 versus combination L-T4 + L-T3 therapy on the serum thyroid hormone levels. We found that L-T4 monotherapy was associated with non-physiologically high FT4 and low FT3 levels, while TSH values did not differ in the two groups.
In the present study we conducted a randomized controlled trial of non-blinded design in 36 hypothyroid premenopausal women without previous therapy in order to assess possible differential influence of the two therapeutic regimens (L-T4 versus combined L-T4, L-T3) on clinical features, lipid profile, bone metabolism markers, bone density, and 24-hour electrocardiographic recording.
Lipoprotein profiles
Elevated levels of total cholesterol, LDL cholesterol, and apolipoprotein B are well documented features of overt hypothyroidism. 11 These changes are reversible upon treatment.
In estimating the dynamics of the lipid profile parameters with the two therapeutic regimens, a favourable effect of combined therapy on serum lipids was observed. Thus, in group B, 6 months after the combination therapy the level of total cholesterol decreased substantially and was significantly lower than the corresponding level in group A (l-T4 monotherapy). Analogous changes were seen in LDL values.
Other authors have reported no significant differences in total cholesterol and lipoproteins between monotherapy with L-T4 and the combination of L-Τ4+L-Τ3. 1, 3, 12 The changes detected in lipoprotein profiles in our study could be explained by the homogeneity of our groups; our study included 36 premenopausal women without any concomitant disease, while other studies were conducted in groups comprised of both men and women, the women being of reproductive age or peri-and postmenopause.
Holter ECG monitoring
The hemodynamic changes typical for hypothyroidism are opposite to those for hyperthyroidism. The most common signs are bradycardia, mild hypertension, and a narrowed pulse pressure. 13 It has been demonstrated that replacement therapy with thyroid hormones reverses all the cardiovascular changes associated with hypothyroidism. [13] [14] [15] We looked for possible negative influence of the combination L-Τ4 + L-Τ3 on the cardiovascular system by Holter ECG monitoring.
There was no significant difference between the two therapeutic regimens in the parameters examined (Table 4) . It is well known that liothyronine reaches peak levels 2 to 4 hours after oral administration. In this connection, the mean heart rate was also analyzed 2 hours after the administration of thyroid hormone preparations. There was no significant difference in this parameter between monotherapy and combined therapy. Thus, the replacement dose of L-Τ3 did not adversely affect the cardiovascular system.
Bone metabolism
The relation between thyroid hormone and bone is well known and was first recognized in the 1890s when von Recklinghausen reported a patient with hyperthyroidism and multiple fractures. Hyperthyroidism (both exogenous and endogenous) accelerates bone turnover and shortens the normal bone remodeling cycle. Thyroid hormones seem to be more detrimental for cortical bone (found in the hip and forearm) than for trabecular bone (found in the spine). 16 There was no difference between treatments in serum osteocalcin. Nevertheless, during combined treatment serum osteocalcin increased by 3.35 ng/ml, whereas during monotherapy it increased by 0.4ng/ml (Table 5 ). In analyzing the dynamics of this parameter it was shown that against a background of the combined therapy a slightly greater stimulation of bone formation took place compared to monotherapy with L-Τ4, which did not reach statistical significance (p>0.05).
However, there was a significant difference in the level of deoxypyridinoline between treatments (p<0.05). In the group of patients who received combined therapy, deoxypyridinoline significantly increased (p<0.05), while no difference was observed in deoxypyridinoline after monotherapy. The difference between the groups after the 6 months' therapy was significant p<0.05 (Table 5 , Figure 2 ). Densitometry demonstrated no significant difference between monotherapy and combined therapy. The absence of a statistically significant change of bone mineral density in our study could be explained by the relatively short duration of the study period.
We can conclude that against a background of the combined L-Τ4+L-Τ3 therapy, a slightly greater activation of bone resorption took place in comparison with monotherapy. It is well known that liothyronine reaches peak levels 2 to 4 hours after oral administration, which may lead to increased levels of T3 at that period of time. Over the past few years efforts have been made to produce LT3 preparations which are slowly absorbed, time-released formulation. 17 The application of such a preparation was recently reported by Hennemann at al. 18 The authors demonstrated that the use of a new, slow-release formulation of LT3, at a low dose, combined with LT4 in treating hypothyroid subjects led to considerable increase of serum T4 and T3 levels and improvement of the T4/T3 ratio and serum TSH as compared to monotherapy. 18 They could not detect peak of T3 in contrast to administration of plain T3. The introduction of a slow-release compound of this nature promises to enrich the arsenal of thyroid hormone preparations. 17 Furthermore, another important aspect in the comparison of these two variants of therapy can be the fact of preference by a patient of one of the two types of treatment. At the final visit the patients were asked which treatment they preferred. Of the 36 patients completing the study, 10 preferred the L-T4+L-T3 regimen (27.8 %) and 8 preferred L-T4 (22.2%). It is an interesting fact that 50% of the patients (18 from 36) had no preference.
Whereas the majority of hypothyroid patients are satisfied with T4 replacement therapy, some are not. How can we explain the dissatisfaction? The first explanation is nonspecific in nature. It could be that simply being aware of having a chronic disease requiring lifelong treatment and regular control visits makes the patients feel unhappy and less healthy. The second explanation may specifically be related to the way in which we replace the deficit in thyroid hormone with only T4, failing to mimic precisely the thyroidal secretion rates of T4 and T3, and the serum concentrations of free T4 and free T3 found in healthy subjects. 19 According to some authors, patients usually preferred the combination of L-T4+L-T3 3, [20] [21] [22] . In the study of Escobar-Morreale H.F. et al, of the 26 patients, 18 (69%) preferred the combination of L-T4+L-T3. 20 Nygaard B et al found that 49% of patients preferred the combination and 15% the monotherapy (p=0.002). 21 Analogous data were found in a large study conducted by Appelhof et al. 22 In this study, 141 patients were randomized to receive either monotherapy with L-T4, or the combination of L-T4+L-T3 at a ratio of 10:1 and 5:1. The study medication was preferred to usual treatment by 29.2%, 41.3%, and 52.2% in the L-T4, 10:1 ratio, and 5:1 ratio groups, respectively. Although patients preferred combined L-T4+L-T3 therapy to usual L-T4 therapy, changes in mood, 20 only a minimal reduction in body weight was found (mean loss of 0.5 kg and 1.7 kg in 15 weeks with the 10:1 and 5:1 combinations, respectively). In our study we also found only minimal, statistically non-significant reduction in body weight in both groups.
CONCLUSION
Compared with L-T4 alone, replacement treatment with combination of L-T4+L-T3 shows improvement in serum lipid profiles, but higher activation of bone resorption. No particular preference for either therapeutic regimen was expressed by the patients. 
